Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 601 to 650 of 1379 results for patients and public

  1. Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable TS ID 10266

    Awaiting development [GID-TA11285] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995

    Awaiting development [GID-TA11525] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy TSID 11996

    Awaiting development [GID-TA11526] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Zavegepant for treating acute migraine TSID 11998

    Awaiting development [GID-TA11527] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Vosoritide for treating achondroplasia in children TSID 12001

    Awaiting development [GID-TA11528] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990

    Awaiting development [GID-TA11519] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436

    Awaiting development [GID-TA11532] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    Awaiting development [GID-TA11535] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease TS ID 11991

    Awaiting development [GID-TA11518] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]

    In development [GID-TA11485] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation TSID 12009

    Awaiting development [GID-TA11534] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Zuranolone for treating severe postnatal depression ID6431

    Awaiting development [GID-TA11356] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Teprotumumab for treating thyroid eye disease ID 6432

    Awaiting development [GID-TA11531] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430

    Awaiting development [GID-TA11530] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Masitinib with riluzole for treating amyotrophic lateral sclerosis TS ID 10728

    Awaiting development [GID-TA11071] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  16. STS101 for treating acute migraine TS ID 11782

    Awaiting development [GID-TA11147] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  17. Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma TS ID 9659

    Awaiting development [GID-TA11111] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  18. Treprostinil diethanolamine for treating pulmonary arterial hypertension TS ID 11772

    Awaiting development [GID-TA11123] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  19. Nitazoxanide for treating the common cold in people 12 years and over TS ID 10548

    Awaiting development [GID-TA11128] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  20. Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765

    Awaiting development [GID-TA11050] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  21. REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443

    Awaiting development [GID-TA11052] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  22. Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 ID4037

    Awaiting development [GID-TA11059] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  23. Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy TS ID 10214

    Awaiting development [GID-TA11069] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  24. Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies TS ID 10330

    Awaiting development [GID-TA11075] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  25. Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable TS ID 10477

    Awaiting development [GID-TA11271] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  26. Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 TS ID 10730

    Awaiting development [GID-TA11105] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  27. Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments TS ID 11830

    Awaiting development [GID-TA11251] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  28. Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults TS ID 10652

    Awaiting development [GID-TA11194] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  29. Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity TS ID 11902

    Awaiting development [GID-TA11417] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  30. Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma TS ID 11823

    Awaiting development [GID-TA11230] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  31. Leriglitazone for treating X-linked andrenoleukodystrophy TS ID 9996

    Awaiting development [GID-TA11393] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  32. Benralizumab for treating hypereosinophilic syndrome in people 12 years and over TS ID 11867

    Awaiting development [GID-TA11360] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  33. Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868

    Awaiting development [GID-TA11361] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  34. Edaravone for treating amyotrophic lateral sclerosis TS ID 11869

    Awaiting development [GID-TA11362] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  35. Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over TS ID 11847

    Awaiting development [GID-TA11372] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  36. Ondansetron for treating alcohol-use disorder TS ID 11884

    Awaiting development [GID-TA11375] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  37. Canagliflozin for treating type 2 diabetes in people 10 to 17 years TS ID 11888

    Awaiting development [GID-TA11377] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  38. Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years TS ID 11885

    Awaiting development [GID-TA11383] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  39. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer TS ID 11910

    Awaiting development [GID-TA11403] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  40. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis TS ID 11905

    Awaiting development [GID-TA11414] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  41. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines TS ID 11903

    Awaiting development [GID-TA11416] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  42. Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over TS ID 10642

    Awaiting development [GID-TA11308] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  43. Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease TS ID 9147

    Awaiting development [GID-TA11327] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  44. Bentracimab for reversing the antiplatelet activity of ticagrelor TS ID 10550

    Awaiting development [GID-TA11354] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  45. Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over TS ID 11865

    Awaiting development [GID-TA11358] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  46. Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia ID6347

    Awaiting development [GID-TA11496] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  47. AI-supported colorectal polyp detection

    Awaiting development [GID-HTE10033] Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  48. Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249

    Awaiting development [GID-TA11254] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  49. Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]

    In development [GID-TA11501] Expected publication date: TBC

    Technology appraisal guidance
    In development

  50. Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]

    In development [GID-TA11422] Expected publication date: TBC

    Technology appraisal guidance
    In development